Advertisement
Screener

Exome Asset Management LLC Historic Quarter Change: USA Other Stocks, Reduced

Exome Asset Management LLC historic quarter change: USA Other Stocks, Reduced

In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Exome Asset Management LLC opened 17 positions, added to 4, reduced 6 and sold out of 29.

  • Q2 2025: Stock VYNE THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 462,801.
  • Q4 2024: Stock MERSANA THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 1,178,570.
  • Q4 2024: Stock BLUEPRINT MEDICINES CORP; Country of operation United States; Class COM; Shares before 36,700.
  • Q2 2024: Stock VYNE THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 415,434.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 2011932), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-15); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-16); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-10-03); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2023-12-31.

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q2 2025VYNE THERAPEUTICS INC
CUSIP 92941V308
United StatesCOM462,801208,970-253,831$731,225$344,801-$386,4242025-08-15
Q4 2024MERSANA THERAPEUTICS INC
CUSIP 59045L106
United StatesCOM1,178,570172,924-1,005,646$2,227,497$249,723-$1,977,7742025-02-14
Q4 2024BLUEPRINT MEDICINES CORP
CUSIP 09627Y109
United StatesCOM36,70031,800-4,900$3,394,750$2,773,596-$621,1542025-02-14
Q2 2024VYNE THERAPEUTICS INC
CUSIP 92941V308
United StatesCOM415,434353,434-62,000$1,275,382$696,265-$579,1172024-10-03
Q1 2024ALPINE IMMUNE SCIENCES INC
CUSIP 02083G100
United StatesCOM173,500117,000-56,500$3,306,910$4,637,880+$1,330,9702024-05-15
Q1 2024INTRA-CELLULAR THERAPIES INC
CUSIP 46116X101
United StatesCOM28,30020,300-8,000$2,026,846$1,404,760-$622,0862024-05-15

Similar Firms

Firm NameCountry13F ValueHoldings
waypoint wealth counselUnited States$0.193B350
Broadway Wealth Solutions, Inc.United States$0.193B95
Ayrshire Capital Management LLCUnited States$0.193B50
JACKSON HILL ADVISORS, LLCUnited States$0.193B13
Banque de Luxembourg S.A.Luxembourg$0.193B77
Topel & Distasi Wealth Management, LLCUnited States$0.193B58
Mitsubishi UFJ Asset Management (UK) Ltd.United Kingdom$0.193B96
Downshift Financial, LLCUnited States$0.193B77
BostonPremier Wealth LLCUnited States$0.194B70
Legal Advantage Investments, Inc.United States$0.194B79